A randomized clinical trial on inhaled ciclesonide for managing acute asthma in the emergency room

Autor(es)

Carlos, Karla ; Carvalho, Luciane Bizari ; Prado, Lucila Bizari ; Fransolin, Carolina ; Atallah, Alvaro Nagib ; do Prado, Gilmar Fernandes

• Tipo de documento: Artigo Científico
• Fonte: São Paulo Medical Journal; v. 140, n. 3, p. 9-pg., 2022-05-01.

Resumo

BACKGROUND: Use of inhaled corticosteroids for managing acute asthma exacerbations has been tested since the 1990s. OBJECTIVE: To compare high doses of inhaled ciclesonide with systemic hydrocortisone for managing acute asthma exacerbations in the emergency department. DESIGN AND SETTING: Double-blind, randomized clinical trial in the public healthcare system of the city METHODS: Fifty-eight patients with moderate or severe asthma with peak flow < 50% of predicted were randomized into two groups. Over the course of four hours, one group received 1440 mcg of inhaled ciclesonide plus hydrocortisone-identical placebo (ciclesonide + placebo), while the other received 500 mg of intravenous hydrocortisone plus ciclesonide-identical placebo (hydrocortisone + placebo). Both groups received short-acting bronchodilators (fenoterol hydrobromide and ipratropium bromide). The research protocol included spirometry, clinical evaluation, vital signs and electrocardiogram monitoring. Data were obtained at 30 (baseline), 60, 90, 120, 180, and 240 minutes. We compared data from baseline to hour 4, between and within groups. RESULTS: Overall, 31 patients received ciclesonide + placebo and 27 received hydrocortisone + placebo. Inhaled ciclesonide was as effective as intravenous hydrocortisone for improving clinical parameters (Borg-scored dyspnea, P = 0.95; sternocleidomastoid muscle use, P = 0.55; wheezing, P = 0.55; respiratory effort, P = 0.95); and spirometric parameters (forced vital capacity, P = 0.50; forced expiratory volume in the first second, P = 0.83; peak expiratory flow, P = 0.51). CONCLUSIONS: Inhaled ciclesonide was not inferior to systemic hydrocortisone for managing acute asthma exacerbations, and it improved both clinical and spirometric parameters. TRIAL REGISTRATION: RBR-6XWC26 - Registro Brasileiro de Ensaios Cl??nicos (http://www.ensaiosclinicos. gov.br/rg/RBR-6xwc26/). (AU)

• Processo FAPESP: 09/16758-4 - Ensaio clínico, randomizado, duplo cego da ciclesonida inalada no tratamento da asma: eficácia, efetividade e impacto sobre o sono
• Beneficiário: Gilmar Fernandes Do Prado
• Modalidade de apoio: Auxílio à Pesquisa - Regular